{"entity":{"id":"nct05859750","kind":"trial","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Cadonilimab, Gemcitabine, Leucovorin (folinic acid) and Oxaliplatin in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.","summary":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT05859750 by Akeso, with 78 participants planned, started 2023-05-25 and due to reach its primary completion in 2025-06. Interventions recorded: AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate and Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05859750","url":"https://clinicaltrials.gov/study/NCT05859750"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["cadonilimab","gemcitabine","leucovorin","oxaliplatin"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05859750","phase":"2","setting":"A Multicenter, Open-label, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Combination With Chemotherapy as First-line Treatment in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","sponsor":"Akeso","started":"2023-05-25","startedType":"actual","enrolled":78,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05859750/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}